Lisata Therapeutics Appoints Jeff Farrow to Board of Directors
Key Highlights
- ➤Lisata appointed Jeffrey Farrow to its Board, effective October 13, 2026
- ➤Farrow fills a newly created seat, expanding Lisata’s Board to eight members
- ➤Farrow will serve on Lisata’s Audit Committee as an independent director
- ➤Lisata is advancing MAR001 and MAR002 in Phase 2b programs
Expert Statements
David Mazzo, Chief Executive Officer of Lisata Therapeutics
“Jeff has helped take multiple companies from the clinic to approval and commercial launch, and he has led several of them through successful strategic outcomes”
David Mazzo, Chief Executive Officer of Lisata Therapeutics
“As we advance our Phase 2b programs in severe hypertriglyceridemia and acromegaly, his financial discipline and public-company experience will be a tremendous asset to our Board.”
Jeffrey Farrow, Chief Financial Officer and Chief Strategy Officer of Tarsus Pharmaceuticals, Inc.
“I’m pleased to join Lisata’s Board at an important point in the Company’s development”
Jeffrey Farrow, Chief Financial Officer and Chief Strategy Officer of Tarsus Pharmaceuticals, Inc.
“I look forward to working with the Board and management team to help build long-term value for patients and stockholders.”
LIBERTY CORNER, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”) today announced the appointment of Jeffrey Farrow to its Board of Directors, effective October 13, 2026.
Mr. Farrow fills a newly created seat, expanding the Board from seven to eight members. He was appointed as a Class III director upon the recommendation of the Nominating and Corporate Governance Committee and will also serve on the Audit Committee. The Board has determined that Mr. Farrow is independent under Nasdaq listing rules.
Get started
Create a free account to read the full story.